Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

PURPOSE: Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers. OBJECTIVE: To assess the cost-effectiveness of statin monotherapy compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaeli, Daniel Tobias, Michaeli, Julia Caroline, Boch, Tobias, Michaeli, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397126/
https://www.ncbi.nlm.nih.gov/pubmed/35015186
http://dx.doi.org/10.1007/s10557-021-07310-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397126/
https://www.ncbi.nlm.nih.gov/pubmed/35015186
http://dx.doi.org/10.1007/s10557-021-07310-y

Ejemplares similares